Literature DB >> 27775549

Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance.

Salvador Alonso, Daniela Hernandez, Yu-Ting Chang, Christian B Gocke, Megan McCray, Ravi Varadhan, William H Matsui, Richard J Jones, Gabriel Ghiaur.   

Abstract

Interactions between multiple myeloma (MM) cells and the BM microenvironment play a critical role in bortezomib (BTZ) resistance. However, the mechanisms involved in these interactions are not completely understood. We previously showed that expression of CYP26 in BM stromal cells maintains a retinoic acid-low (RA-low) microenvironment that prevents the differentiation of normal and malignant hematopoietic cells. Since a low secretory B cell phenotype is associated with BTZ resistance in MM and retinoid signaling promotes plasma cell differentiation and Ig production, we investigated whether stromal expression of the cytochrome P450 monooxygenase CYP26 modulates BTZ sensitivity in the BM niche. CYP26-mediated inactivation of RA within the BM microenvironment prevented plasma cell differentiation and promoted a B cell-like, BTZ-resistant phenotype in human MM cells that were cocultured on BM stroma. Moreover, paracrine Hedgehog secretion by MM cells upregulated stromal CYP26 and further reinforced a protective microenvironment. These results suggest that crosstalk between Hedgehog and retinoid signaling modulates BTZ sensitivity in the BM niche. Targeting these pathological interactions holds promise for eliminating minimal residual disease in MM.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27775549      PMCID: PMC5127663          DOI: 10.1172/JCI88152

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  47 in total

1.  The development of biologic end points in patients treated with differentiation agents: an experience of retinoids in prostate cancer.

Authors:  W K Kelly; I Osman; V E Reuter; T Curley; W D Heston; D M Nanus; H I Scher
Journal:  Clin Cancer Res       Date:  2000-03       Impact factor: 12.531

2.  Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth.

Authors:  Michael Quante; Shui Ping Tu; Hiroyuki Tomita; Tamas Gonda; Sophie S W Wang; Shigeo Takashi; Gwang Ho Baik; Wataru Shibata; Bethany Diprete; Kelly S Betz; Richard Friedman; Andrea Varro; Benjamin Tycko; Timothy C Wang
Journal:  Cancer Cell       Date:  2011-02-15       Impact factor: 31.743

3.  CXCR4 Is Required for Leukemia-Initiating Cell Activity in T Cell Acute Lymphoblastic Leukemia.

Authors:  Diana Passaro; Marta Irigoyen; Claire Catherinet; Stéphanie Gachet; Cindy Da Costa De Jesus; Charlène Lasgi; Christine Tran Quang; Jacques Ghysdael
Journal:  Cancer Cell       Date:  2015-06-08       Impact factor: 31.743

4.  BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.

Authors:  Aldo M Roccaro; Antonio Sacco; Patricia Maiso; Abdel Kareem Azab; Yu-Tzu Tai; Michaela Reagan; Feda Azab; Ludmila M Flores; Federico Campigotto; Edie Weller; Kenneth C Anderson; David T Scadden; Irene M Ghobrial
Journal:  J Clin Invest       Date:  2013-04       Impact factor: 14.808

5.  Sonic hedgehog promotes desmoplasia in pancreatic cancer.

Authors:  Jennifer M Bailey; Benjamin J Swanson; Tomofumi Hamada; John P Eggers; Pankaj K Singh; Thomas Caffery; Michel M Ouellette; Michael A Hollingsworth
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

Review 6.  The pathogenesis of the bone disease of multiple myeloma.

Authors:  Claire M Edwards; Junling Zhuang; Gregory R Mundy
Journal:  Bone       Date:  2008-02-21       Impact factor: 4.398

7.  Retinoid signaling regulates breast cancer stem cell differentiation.

Authors:  Christophe Ginestier; Julien Wicinski; Nathalie Cervera; Florence Monville; Pascal Finetti; François Bertucci; Max S Wicha; Daniel Birnbaum; Emmanuelle Charafe-Jauffret
Journal:  Cell Cycle       Date:  2009-10-10       Impact factor: 4.534

8.  A paracrine requirement for hedgehog signalling in cancer.

Authors:  Robert L Yauch; Stephen E Gould; Suzie J Scales; Tracy Tang; Hua Tian; Christina P Ahn; Derek Marshall; Ling Fu; Thomas Januario; Dara Kallop; Michelle Nannini-Pepe; Karen Kotkow; James C Marsters; Lee L Rubin; Frederic J de Sauvage
Journal:  Nature       Date:  2008-08-27       Impact factor: 49.962

9.  Absence of natural intracellular retinoids in mouse bone marrow cells and implications for PML-RARA transformation.

Authors:  H Niu; J Chacko; G Hadwiger; J S Welch
Journal:  Blood Cancer J       Date:  2015-02-27       Impact factor: 11.037

10.  A versatile viral system for expression and depletion of proteins in mammalian cells.

Authors:  Eric Campeau; Victoria E Ruhl; Francis Rodier; Corey L Smith; Brittany L Rahmberg; Jill O Fuss; Judith Campisi; Paul Yaswen; Priscilla K Cooper; Paul D Kaufman
Journal:  PLoS One       Date:  2009-08-06       Impact factor: 3.240

View more
  20 in total

1.  CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity.

Authors:  Meisam Naeimi Kararoudi; Yuya Nagai; Ezgi Elmas; Marcelo de Souza Fernandes Pereira; Syed Abbas Ali; Philip Hollingsworth Imus; Darren Wethington; Ivan Marques Borrello; Dean Anthony Lee; Gabriel Ghiaur
Journal:  Blood       Date:  2020-11-19       Impact factor: 22.113

Review 2.  Targeting the tumour stroma to improve cancer therapy.

Authors:  Kenneth C Valkenburg; Amber E de Groot; Kenneth J Pienta
Journal:  Nat Rev Clin Oncol       Date:  2018-06       Impact factor: 66.675

3.  Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors.

Authors:  Yu-Ting Chang; Daniela Hernandez; Salvador Alonso; Minling Gao; Meng Su; Gabriel Ghiaur; Mark J Levis; Richard J Jones
Journal:  Blood Adv       Date:  2019-03-26

Review 4.  Retinoic acid, CYP26, and drug resistance in the stem cell niche.

Authors:  Salvador Alonso; Richard J Jones; Gabriel Ghiaur
Journal:  Exp Hematol       Date:  2017-07-25       Impact factor: 3.084

5.  The role of GLI2-ABCG2 signaling axis for 5Fu resistance in gastric cancer.

Authors:  Beiqin Yu; Dongsheng Gu; Xiaoli Zhang; Bingya Liu; Jingwu Xie
Journal:  J Genet Genomics       Date:  2017-07-25       Impact factor: 4.275

6.  CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement.

Authors:  Matteo Claudio Da Vià; Antonio Giovanni Solimando; Andoni Garitano-Trojaola; Santiago Barrio; Umair Munawar; Susanne Strifler; Larissa Haertle; Nadine Rhodes; Eva Teufel; Cornelia Vogt; Constantin Lapa; Andreas Beilhack; Leo Rasche; Hermann Einsele; K Martin Kortüm
Journal:  Oncologist       Date:  2019-10-18

7.  CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement.

Authors:  Matteo Claudio Da Vià; Antonio Giovanni Solimando; Andoni Garitano-Trojaola; Santiago Barrio; Umair Munawar; Susanne Strifler; Larissa Haertle; Nadine Rhodes; Eva Teufel; Cornelia Vogt; Constantin Lapa; Andreas Beilhack; Leo Rasche; Hermann Einsele; K Martin Kortüm
Journal:  Oncologist       Date:  2019-10-18

Review 8.  Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment.

Authors:  Gabriel Ghiaur; Mark Levis
Journal:  Hematol Oncol Clin North Am       Date:  2017-05-18       Impact factor: 3.722

Review 9.  The Role of Notch, Hedgehog, and Wnt Signaling Pathways in the Resistance of Tumors to Anticancer Therapies.

Authors:  Vivek Kumar; Mohit Vashishta; Lin Kong; Xiaodong Wu; Jiade J Lu; Chandan Guha; B S Dwarakanath
Journal:  Front Cell Dev Biol       Date:  2021-04-22

Review 10.  The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies.

Authors:  Taylor Harding; Linda Baughn; Shaji Kumar; Brian Van Ness
Journal:  Leukemia       Date:  2019-01-25       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.